Login to Your Account



Potential $130M Per Program

Deciphera's B-Raf Inhibitor Program Lands Deal with Lilly

By Jennifer Boggs


Monday, October 6, 2008
Privately held Deciphera Pharmaceuticals LLC signed its first big pharma deal, licensing rights to four preclinical B-Raf kinase inhibitors to Eli Lilly and Co. for the development of oncology drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription